Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer : Phase III LYNK-003
Oxaliplatin-based chemotherapy with a regimen such as FOLFOX with or without targeted therapy is a standard of care option for advanced colorectal cancer; however, long-term exposure to oxaliplatin is associated with cumulative toxicity. Growing evidence suggests maintenance therapy with a less intensive regimen after platinum-based induction therapy can provide continuing benefit with reduced toxicity. We describe the rationale and design of the Phase III LYNK-003 trial, which will evaluate the efficacy and safety of olaparib with or without bevacizumab compared with 5-fluoruracil plus bevacizumab in patients with unresectable or metastatic colorectal cancer that has not progressed on an induction course of FOLFOX plus bevacizumab. The primary end point is progression-free survival by independent central review; secondary end points include overall survival, objective response, duration of response and safety. Clinical trial registration: NCT04456699.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 17(2021), 36 vom: 13. Dez., Seite 5013-5022 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Tae Won [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2022 Date Revised 20.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT04456699 Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2021-0899 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333174038 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333174038 | ||
| 003 | DE-627 | ||
| 005 | 20240320232643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2021-0899 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM333174038 | ||
| 035 | |a (NLM)34779646 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Tae Won |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer |b Phase III LYNK-003 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2022 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04456699 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Oxaliplatin-based chemotherapy with a regimen such as FOLFOX with or without targeted therapy is a standard of care option for advanced colorectal cancer; however, long-term exposure to oxaliplatin is associated with cumulative toxicity. Growing evidence suggests maintenance therapy with a less intensive regimen after platinum-based induction therapy can provide continuing benefit with reduced toxicity. We describe the rationale and design of the Phase III LYNK-003 trial, which will evaluate the efficacy and safety of olaparib with or without bevacizumab compared with 5-fluoruracil plus bevacizumab in patients with unresectable or metastatic colorectal cancer that has not progressed on an induction course of FOLFOX plus bevacizumab. The primary end point is progression-free survival by independent central review; secondary end points include overall survival, objective response, duration of response and safety. Clinical trial registration: NCT04456699 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-fluorouracil | |
| 650 | 4 | |a FOLFOX | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a folinic acid | |
| 650 | 4 | |a irinotecan | |
| 650 | 4 | |a maintenance therapy | |
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a oxaliplatin | |
| 650 | 7 | |a Bevacizumab |2 NLM | |
| 650 | 7 | |a 2S9ZZM9Q9V |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a olaparib |2 NLM | |
| 650 | 7 | |a WOH1JD9AR8 |2 NLM | |
| 650 | 7 | |a Phthalazines |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 700 | 1 | |a Taieb, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Gurary, Ellen B |e verfasserin |4 aut | |
| 700 | 1 | |a Lerman, Nati |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Takayuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 17(2021), 36 vom: 13. Dez., Seite 5013-5022 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:36 |g day:13 |g month:12 |g pages:5013-5022 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2021-0899 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 36 |b 13 |c 12 |h 5013-5022 | ||